Trial reportBMC cancer2026
Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07143955 (A Randomized Controlled Trial of a Targeted Dietary Intervention to Reshape Gut Microbiota and Lipid Metabolism for Enhancing Anti-Tumor Immunity and Prognosis in Patients With Hepatocellular Carcinoma), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of a Targeted Dietary Intervention to Reshape Gut Microbiota and Lipid Metabolism for Enhancing Anti-Tumor Immunity and Prognosis in Patients With Hepatocellular Carcinoma
Who cites it
4 citing papers in PubMed.
- Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026Review
- Diet-Microbiota-Immune Interactions in Hepatocellular Carcinoma: An Immunometabolic and Spatial Perspective.Nutrients · 2026Review
- Review
- Beyond survival: psychoneuroimmunology-driven cancer psychological rehabilitation-a paradigm shift from symptom management to biobehavioral remodeling.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe gut microbiota is increasingly recognized as a key modulator of cancer pathogenesis and treatment response. We aimed to investigate the efficacy of a targeted dietary intervention on clinical outcomes, gut microbiota, lipid metabolism, and systemic immunity in patients with hepatocellular carcinoma (HCC).
methodsIn this single-center, prospective, randomized controlled trial, 100 patients with primary HCC were enrolled and randomly assigned (1:1) to an experimental group (n = 50), receiving a structured dietary intervention including probiotics, prebiotics, and specific dietary advice, or a control group (n = 50), receiving routine dietary care. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included changes in gut microbiota composition (16S rRNA sequencing), serum lipid profiles, immune cell subsets (flow cytometry), and quality of life (WHOQOL-100).
resultsAfter a median follow-up of 12 months, the experimental group showed significantly longer median PFS (9.4 vs. 7.3 months; Hazard Ratio [HR] = 0.52, 95% CI: 0.34–0.79, P < 0.01) and median OS (27.7 vs. 22.6 months; HR = 0.61, 95% CI: 0.42–0.88, P = 0.008). The intervention significantly increased microbial α-diversity and enriched beneficial genera such as Bifidobacterium and Lactobacillus. This was accompanied by improved lipid metabolism (reduced serum cholesterol and triglycerides) and a shift towards an anti-tumor immune profile, including increased CD8 + T cells and decreased regulatory T cells (Tregs). Quality of life scores were also significantly higher in the experimental group (P < 0.001).
conclusionA targeted dietary intervention effectively modulates the gut microbiota, lipid metabolism, and systemic immunity in HCC patients, translating into significant improvements in survival and quality of life. These findings support microbiota-targeted dietary therapy as a promising adjunctive strategy in HCC management.
trial registrationThis study was registered with ClinicalTrials.gov (Identifier: NCT07143955; date: 19/08/2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.